Orthofix International N.V. (NASDAQ:OFIX) – Equities researchers at SunTrust Banks issued their Q1 2018 earnings per share (EPS) estimates for shares of Orthofix International in a report released on Sunday. SunTrust Banks analyst B. Nudell expects that the medical device company will earn $0.32 per share for the quarter. SunTrust Banks has a “Buy” rating and a $67.00 price target on the stock. SunTrust Banks also issued estimates for Orthofix International’s Q2 2018 earnings at $0.48 EPS, Q3 2018 earnings at $0.50 EPS, Q4 2018 earnings at $0.56 EPS, FY2018 earnings at $1.86 EPS, FY2019 earnings at $2.23 EPS, FY2020 earnings at $2.44 EPS and FY2021 earnings at $2.55 EPS.
A number of other research firms have also commented on OFIX. BidaskClub raised Orthofix International from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. ValuEngine raised Orthofix International from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Gabelli reissued a “buy” rating on shares of Orthofix International in a report on Wednesday, February 28th. Finally, Zacks Investment Research lowered Orthofix International from a “buy” rating to a “hold” rating in a report on Wednesday, November 8th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Orthofix International presently has a consensus rating of “Buy” and an average price target of $57.42.
Shares of Orthofix International (NASDAQ:OFIX) opened at $59.06 on Wednesday. The company has a market capitalization of $1,075.59, a price-to-earnings ratio of 35.85, a price-to-earnings-growth ratio of 3.22 and a beta of 0.24. Orthofix International has a fifty-two week low of $33.90 and a fifty-two week high of $59.26.
Orthofix International (NASDAQ:OFIX) last posted its earnings results on Monday, February 26th. The medical device company reported $0.52 EPS for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.02. The business had revenue of $116.90 million during the quarter, compared to analyst estimates of $116.93 million. Orthofix International had a return on equity of 10.66% and a net margin of 1.43%. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.42 EPS.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oakview Capital Management L.P. purchased a new position in shares of Orthofix International in the third quarter valued at about $12,756,000. BlackRock Inc. lifted its position in shares of Orthofix International by 8.5% in the fourth quarter. BlackRock Inc. now owns 2,464,012 shares of the medical device company’s stock valued at $134,781,000 after acquiring an additional 192,830 shares in the last quarter. Millennium Management LLC lifted its position in shares of Orthofix International by 25.6% in the fourth quarter. Millennium Management LLC now owns 651,969 shares of the medical device company’s stock valued at $35,663,000 after acquiring an additional 132,743 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Orthofix International by 29.4% in the fourth quarter. Renaissance Technologies LLC now owns 558,679 shares of the medical device company’s stock valued at $30,560,000 after acquiring an additional 126,979 shares in the last quarter. Finally, Allianz Asset Management GmbH purchased a new position in shares of Orthofix International in the fourth quarter valued at about $4,067,000. Institutional investors own 93.09% of the company’s stock.
In other news, insider Bradley V. Niemann sold 5,547 shares of the firm’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $52.08, for a total value of $288,887.76. Following the transaction, the insider now directly owns 34,631 shares in the company, valued at approximately $1,803,582.48. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 5.60% of the company’s stock.
Orthofix International Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.